Terms: = Bone cancer AND FAS, FAS1, 355, ENSG00000026103, FASTM, APO-1, P25445, CD95, ALPS1A, TNFRSF6, APT1 AND Clinical Outcome
2 results:
1. Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).
Martin-Broto J; Redondo A; Valverde C; Vaz MA; Mora J; Garcia Del Muro X; Gutierrez A; Tous C; Carnero A; Marcilla D; Carranza A; Sancho P; Martinez-Trufero J; Diaz-Beveridge R; Cruz J; Encinas V; Taron M; Moura DS; Luna P; Hindi N; Lopez-Pousa A
Ann Oncol; 2017 Dec; 28(12):2994-2999. PubMed ID: 29045512
[TBL] [Abstract] [Full Text] [Related]
2. fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of fas ligand tumor counterattack.
Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
[TBL] [Abstract] [Full Text] [Related]
